Donohue JF, Kerwin E, Sethi S, et al. - Given good tolerability and a favorable benefit-risk profile of revefenacin (a long-acting muscarinic antagonist) reported in a recent 52-week safety trial in chronic obstructive pulmonary disease (COPD) patients, researchers define exploratory efficacy and health outcomes in patients taking revefenacin 175 μg or 88 μg daily during the 52-week trial. Participants were 1,055 patients suffering from moderate to very severe COPD. The participants received revefenacin 175 μg or 88 μg in a double-blind manner, or open-label active control tiotropium in this randomized, parallel-group trial. Findings revealed that trough forced expiratory volume in 1 s and respiratory health outcomes from baseline were significantly improved persistently as a result of treatment with 175-μg revefenacin over 52 weeks, and therefore, its use as a once-daily bronchodilator for the nebulized treatment of patients with COPD was supported.